Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Vaginal yeast infections during pregnancy

Derrick Soong and Adrienne Einarson
Canadian Family Physician March 2009, 55 (3) 255-256;
Derrick Soong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne Einarson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION My pregnant patients often present with symptomatic vaginal yeast infections. Are the medications commonly used for the management of yeast infections safe to use during pregnancy?

ANSWER Existing data indicate that exposure to oral and topical antifungals, topical antiseptics, or corticosteroids during pregnancy is not associated with increased risk of major malformations. Topical azole antifungals are the recommended treatment during pregnancy for at least 7 days owing to increased efficacy. Topical corticosteroids can be used for symptomatic relief.

Vulvovaginal candidiasis (VVC), often referred to as a yeast infection, is a common gynecologic ailment, affecting 3 out of 4 women in their lifetimes.1 More than 40% of affected women will have 2 or more VVC episodes,2,3 and infection occurs more frequently in pregnant women. It is believed that higher estrogen levels and higher glycogen content in vaginal secretions during pregnancy increase a woman’s risk of developing VVC.4 As VVC is so common in women during their childbearing years, it is important to understand the pathology of this disease as well as the safety or risks of drugs used to treat it during pregnancy.

Vulvovaginal candidiasis is caused by overabundant growth of yeast cells, belonging to the Candida species, in the vaginal mucosa. Candida albicans infection occurs in the vast majority (80% to 90%) of diagnosed VVC cases, while infection with other species, such as Candida glabrata or Candida tropicalis, occurs less frequently.5 With adequate pharmacotherapy and avoidance of contributing factors (eg, douching, wearing tight pants), VVC and associated symptoms resolve in a short period of time. There are several treatment options for Candida infection, such as antifungals and antiseptics, with corticosteroids as a useful addition for pruritus and erythema.

Antifungals

Antifungal agents commercially available for the treatment of VVC in Canada include the following: imidazole antifungals (eg, butoconazole, clotrimazole, miconazole), triazole antifungals (eg, fluconazole, terconazole), and polyene antifungals (eg, nystatin). These agents are available in oral and topical formulations. The topical formulations of imidazole and triazole antifungals, collectively known as azole antifungals, are considered the therapy of choice during pregnancy owing to the safety data collected from animals as well as humans. Prospective and observational studies involving the use of topical antifungals did not reveal an increased risk of major malformations when mothers were exposed any time during pregnancy, and the authors considered them generally safe.6 Systemic absorption of these topical medications is minimal, posing little risk of transfer to the unborn baby. Azole therapy should be recommended for 7 days instead of a shorter duration because of improved treatment success.7,8

Oral fluconazole should be considered as a second-line therapy to treat VVC. There have been case reports in which fluconazole has been associated with major malformations, but only at higher doses (≥ 400 mg/d).9,10 There is no increased risk of major malformations associated with short-term use of 150 mg of fluconazole to treat VVC.11

Topical nystatin is a safe alternative to azole anti-fungals that has been extensively studied in the first trimester of pregnancy. As nystatin has negligible systemic absorption, no associated risk of major malformations has been observed in numerous trials.6 The recommended dose of nystatin during pregnancy is 100 000 units intravaginally once daily for 2 weeks.1

Antiseptics

Boric acid has been studied in the treatment of VVC. Although it is not commercially available, boric acid is an alternative to the antifungal agents. There is little published information regarding the safety of boric acid in humans. A recent retrospective case-control study from Hungary suggested a weak association between boric acid exposure during pregnancy and major malformations, but the association did not reach statistical significance.12 Unless the vaginal epithelium is severely excoriated, only a limited amount of boric acid is systemically absorbed13; therefore, in most cases the amount absorbed through the vaginal mucosa is minimal and exposure risk to the unborn fetus is theoretical. The typical dose of boric acid is 600 mg intravaginally per night for 14 consecutive nights.14

Corticosteroids

Symptoms such as itchiness and redness commonly occur in VVC, and topical corticosteroids can be prescribed to alleviate these acute symptoms. The safety of corticosteroid use during pregnancy has been discussed in a previous Motherisk Update.15 A meta-analysis conducted by Park-Wyllie et al, combining 5 prospective human studies, found that for mothers who were exposed to oral corticosteroids, there was a non-significant increased odds ratio for total major malformations. There was a small but statistically significant increased risk of cleft palate compared with controls (odds ratio 3.35, 95% confidence interval 1.97 to 5.69).16 For topical corticosteroids, approximately 3% of the dose applied onto the skin is systemically absorbed.17 Two population-based studies found no increased risk of major malformations in the babies of mothers who used topical corticosteroids during pregnancy.18,19

Conclusion

It is important to treat VVC infections in pregnant women, and there are safe medications that can be used. Topical azole antifungals are well studied, commercially available, and do not require a physician’s prescription. Seven days of therapy is highly recommended, as shorter duration of treatment is associated with treatment failures. Alternatives to topical azoles include topical nystatin and oral fluconazole. Topical nystatin or oral fluconazole should be used if a patient cannot use topical azole antifungals. For symptomatic relief of redness or itchiness, short-term use of a low-potency topical corticosteroid is considered safe to use in pregnancy.

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Mr Soong is a doctoral candidate at the Leslie Dan Faculty of Pharmacy at the University of Toronto. Ms Einarson is Assistant Director of the Motherisk Program.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.

Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    Das NevesJPintoETeixeiraBDiasGRochaPCunhaTLocal treatment of vulvovaginal candidosis: general and practical considerationsDrugs200868131787802
    OpenUrlCrossRefPubMed
  2. ↵
    FerrerJVaginal candidosis: epidemiological and etiological factorsInt J Gynaecol Obstet200071Suppl 1S217
    OpenUrlCrossRefPubMed
  3. ↵
    EschenbachDAChronic vulvovaginal candidiasisN Engl J Med200435198512
    OpenUrlCrossRefPubMed
  4. ↵
    MonifGRBakerDAMonifGRBakerDACandida albicansInfectious diseases in obstetrics and gynecology5th edNew York, NYParthenon Press200340521
  5. ↵
    BaronEJCassellGHDuffyLBEschenbachJRGreenwoodSMHarveyNEBaronEJLaboratory diagnosis of female genital tract infectionsCumulative techniques and procedures in clinical microbiology (Cumitech) 17AWashington, DCASM Press1993128
  6. ↵
    KingCTRogersPDClearyJDChapmanSWAntifungal therapy during pregnancyClin Infect Dis1998275115160
    OpenUrlAbstract/FREE Full Text
  7. ↵
    DoeringPLSantiagoTMDrugs for treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimensDICP19902411107883
    OpenUrlPubMed
  8. ↵
    YoungGLJewellDTopical treatment for vaginal candidiasis (thrush) in pregnancyCochrane Database Syst Rev20014CD00022510.1002/14651858.CD000225
    OpenUrlCrossRefPubMed
  9. ↵
    LeeBEFeinbergMAbrahamJJMurthyARCongenital malformations in an infant born to a woman treated with fluconazolePediatr Infect Dis J1992111210624
    OpenUrlPubMed
  10. ↵
    PursleyTJBlomquistIKAbrahamJAndersenHFBartleyJAFluconazole-induced congenital anomalies in three infantsClin Infect Dis199622233640
    OpenUrlAbstract/FREE Full Text
  11. ↵
    NørgaardMPedersenLGislumMErichsenRSøgaardKKSchonheyderHCMaternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort studyJ Antimicrob Chemother20086211726Epub 2008 Apr 9
    OpenUrlAbstract/FREE Full Text
  12. ↵
    AcsNBánhidyFPuhóECzeizelAETeratogenic effects of vaginal boric acid treatment during pregnancyInt J Gynaecol Obstet2006931556Epub 2006 Mar 10
    OpenUrlPubMed
  13. ↵
    FailPAChapinREPriceCJHeindelJJGeneral, reproductive, developmental and endocrine toxicity of boronated compoundsReprod Toxicol1998121118
    OpenUrlCrossRefPubMed
  14. ↵
    PappasPGRexJHSobelJDFillerSGDismukesWEWalshTJGuidelines for the treatment of candidiasisClin Infect Dis200438216189Epub 2003 Dec 19
    OpenUrlFREE Full Text
  15. ↵
    OrenDNulmanIMakhijaMItoSKorenGUsing corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk?Can Fam Physician20045010835
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Park-WyllieLMazzottaPPastuszakAMorettiMEBeiqueLHunnisettLBirth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studiesTeratology200062638592
    OpenUrlCrossRefPubMed
  17. ↵
    TauscherAEFleischerABJrPhelpsKCFeldmanSRPsoriasis and pregnancyJ Cutan Med Surg20026656170Epub 2002 Oct 9
    OpenUrlPubMed
  18. ↵
    CzeizelAERockenbauerMPopulation-based case-control study of teratogenic potential of corticosteroidsTeratology199756533540
    OpenUrlCrossRefPubMed
  19. ↵
    MygindHThulstrupAMPedersenLLarsenHRisk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancyActa Obstet Gynecol Scand20028132349
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (3)
Canadian Family Physician
Vol. 55, Issue 3
1 Mar 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vaginal yeast infections during pregnancy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vaginal yeast infections during pregnancy
Derrick Soong, Adrienne Einarson
Canadian Family Physician Mar 2009, 55 (3) 255-256;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Vaginal yeast infections during pregnancy
Derrick Soong, Adrienne Einarson
Canadian Family Physician Mar 2009, 55 (3) 255-256;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Antifungals
    • Antiseptics
    • Corticosteroids
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study
  • The ABCs of Candida albicans Multidrug Transporter Cdr1
  • Interactions Among Urogenital, Intestinal, Skin, and Oral Infections in Pregnant and Lactating Panamanian Ngabe Women: A Neglected Public Health Challenge
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire